📣 Notice: Short Maintenance Tonight (May 19th)
Due to increasing user numbers, we’re upgrading our servers this evening. StocksGuide will be unavailable for about 5–10 minutes between 4:00 PM and 5:00 PM (EDT / New York time). Afterwards, you’ll continue to benefit from fast and stable site performance. Thank you for your understanding! Your StocksGuide Team

Protara Therapeutics Inc Stock

$3.26

2.19% today

Nasdaq, May 19, 04:49 pm CET

ISIN

US74365U1079

Symbol

TARA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Protara Therapeutics Inc Stock price

$3.19

-22.61 87.64% 5Y

Nasdaq, Closing price Fri, May 16 2025

+0.08 2.57%

ISIN

US74365U1079

Symbol

TARA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$123.08m
Enterprise Value	$2.95m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	0.78
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-51.43m
Free Cash Flow (TTM) Free Cash Flow	$-40.25m
Cash position	$124.36m
EPS (TTM) EPS	$-1.73
P/E forward	negative
Short interest	6.58%

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Get Started for Free Today

Protara Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Protara Therapeutics Inc forecast:

6x Buy

100%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Protara Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Protara Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	0.60 0.60	17% 17% -
Gross Profit	-0.60 -0.60	17% 17% -
- Selling and Administrative Expenses	17 17	3% 3% -
- Research and Development Expense	33 33	20% 20% -
EBITDA	-51 -51	13% 13% -
- Depreciation and Amortization	0.60 0.60	17% 17% -
EBIT (Operating Income) EBIT	-51 -51	12% 12% -
Net Profit	-45 -45	7% 7% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Protara Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

6 days ago

Protara Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences:

Neutral

GlobeNewsWire

●

11 days ago

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

Neutral

GlobeNewsWire

●

18 days ago

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to six newly-hired employees.

More Protara Therapeutics Inc News

Company Profile

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.

Head office	United States
CEO	Jesse Shefferman
Employees	33
Founded	2006
Website	www.protaratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now